ACPA status could inform treatment and preventive strategies ...

Sponsored by Regeneron and Sanofi. It was a perfect day for a shark dive. The skies were blue and the water off Guadalupe Island was crystal clear. Shane, a software engineer by trade and adventurer ...

In an interview with The American Journal of Managed Care ® (AJMC ®) at the American Thoracic Society International ...

In the bustling wellness market of 2026, a new product has captured significant attention: Kinzeno Triple Action Massage Gel.

Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA ® (lorlatinib, a third-generation ALK inhibitor, available in Europe ...

The Los Angeles County Department of Public Health (LAC DPH) is investigating a cluster of Brucella melitensis (brucellosis) infections among adults residing in South Los Angeles County.  Each ...

Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial ...

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or ...

Citius Oncology, Inc. ("Citius Oncology") , an oncology?focused biopharmaceutical company and majority?owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , today announced that ...

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, ...

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemiaMitapivat is now approved for thalassemia in the U.S., Sa ...